The Food and Drug Administration (FDA) has extended the review period for Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis by another three months, to give time for a comprehensive review of additional information under the NDA (new drug application), Merck KGaA announced today. The Priority Review period's end has been extended from November 28th 2010 to February 28th 2011. Bernhard Kirschbaum, Head of Global Research and Development...
More...
More...